INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10576824
	Filing Date		2004-10-22
	First Named Inventor Phipp		s et al.
	Art Unit		1617
	Examiner Name		
	Attorney Docket Number		176/61654

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number 1 Is		Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6429226	В1	2006-08	3-06	STJERNSCHANTZ et al.				
	2	6399640	В1	2002-06	6-04	SAHOO et al.				
If you wisl	n to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.			_
U.S.PATENT APPLICATION PUBLICATIONS										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to a	dd additional U.S. Publi	shed Ap	plication	citatio	ı n information p	olease click the Ade	butto	on.	_
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	miner Cite Foreign Document Country No Number³ Code² j		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5		
	1									
If you wisl	n to a	⊔ dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	buttor	1	_
			NON	J-PATFI	NT LITE	RATURE DO	CUMENTS			_

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10576824			
Filing Date		2004-10-22			
First Named Inventor Phipp		s et al.			
Art Unit		1617			
Examiner Name					
Attorney Docket Number		176/6165/			

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T 5
	1	ANDRE et al., Platelet-Derived CD40L The Switch-Hitting Player of Cardiovascular Disease, Circulation, 2002, 896-899, Vol. 106, United States.	
	2	MARX et al., Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease, Circulation, 2003, 1954-1957, Vol. 107, United States.	
	3	ALAIMO et al., Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand, Circulation, 2002, 2849-2854, Vol. 105, United States.	
	4	PRASAD et al., Soluble CD40 Ligand Induces Beta 3 Integrin Tyrosine Phosphorylation and Triggers Platelet Activation by Outside-In Signaling, PNAS, October 14, 2003, 12367-12371, Vol. 100:21, United States.	
	5	SANGUIGNI et al., Short-Term Treatment With Atorvestatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients, Circulation, 2005, 412-419, Vol. 111, United States.	
	6	AKBIYIK et al., Human Bone Marrow Megakaryocytes and Platelets Express PPARy, and PPARy Agonists Blunt Platelet Release of CD40 Ligand and Thromboxanes, Blood, September 2004, 1361-1368, Vol. 104:5, United States.	
	7	SMYTH et al., PPARy Agonists: A new Strategy for Antithrombotic Therapy, J Thromb Haemost, 2005, 2147-2148, Vol. 3, United States.	
	8	MORENO et al., The Year in Atherothrombosis, J Am Coll Cardiol, 2004, 2099-2110, Vol. 44, United States.	
	9	CAPLUS Accession 2004:84523 for CUI et al., Protective Effects of PGE on Vascular Endothelial Function in Diabetic Atherosclerotic Rabbits, Tianjin Yiyao, 2002, 616-619, Vol. 30:10, China.	
	10	MARX et al., Antidiabatic PPARy-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Persons with Coronary Artery Disease, Arterioscler. Thromb. Vasc. Biol., 2003, 283-288, Vol. 23, United States.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10576824		
Filing Date		2004-10-22		
First Named Inventor Phipp		s et al.		
Art Unit		1617		
Examiner Name				
Attorney Docket Number		176/6165/		

	11	International	Search Report, 2005-10-12.						
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button								
EXAMINER SIGNATURE									
Examiner	Signa	iture	Date Considered	- 14 T					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

¹ See Kind Codes of USPTO Patent Documents at https://www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.